Carotid and Renal Artery Stents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

Carotid and Renal Artery Stents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update


Summary

GlobalData's Medical Devices sector report, “Carotid and Renal Artery Stents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Carotid and Renal Artery Stents pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Carotid artery stents are expandable tubes that are implanted in narrowed carotid arteries to increase the flow of blood. Carotid arteries become narrowed due to plaque formation and buildup in the inner surface of the arteries.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Carotid and Renal Artery Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Carotid and Renal Artery Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Carotid and Renal Artery Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • About GlobalData
  • Introduction
    • Carotid and Renal Artery Stents Overview
  • Products under Development
    • Carotid and Renal Artery Stents - Pipeline Products by Stage of Development
      • Table Figure 1: Carotid and Renal Artery Stents - Pipeline Products by Stage of Development
      • Table Carotid and Renal Artery Stents - Pipeline Products by Stage of Development
    • Carotid and Renal Artery Stents - Pipeline Products by Segment
      • Table Figure 2: Carotid and Renal Artery Stents - Pipeline Products by Segment
      • Table Carotid and Renal Artery Stents - Pipeline Products by Segment
    • Carotid and Renal Artery Stents - Pipeline Products by Territory
      • Table Figure 3: Carotid and Renal Artery Stents - Pipeline Products by Territory
      • Table Carotid and Renal Artery Stents - Pipeline Products by Territory
    • Carotid and Renal Artery Stents - Pipeline Products by Regulatory Path
      • Table Figure 4: Carotid and Renal Artery Stents - Pipeline Products by Regulatory Path
      • Table Carotid and Renal Artery Stents - Pipeline Products by Regulatory Path
    • Carotid and Renal Artery Stents - Pipeline Products by Estimated Approval Date
      • Table Figure 5: Carotid and Renal Artery Stents - Pipeline Products by Estimated Approval Date
      • Table Carotid and Renal Artery Stents - Pipeline Products by Estimated Approval Date
    • Carotid and Renal Artery Stents - Ongoing Clinical Trials
      • Table Figure 6: Carotid and Renal Artery Stents - Ongoing Clinical Trials
      • Table Carotid and Renal Artery Stents - Ongoing Clinical Trials
  • Carotid and Renal Artery Stents - Pipeline Products under Development by Companies
    • Carotid and Renal Artery Stents Companies - Pipeline Products by Stage of Development
      • Table Carotid and Renal Artery Stents Companies - Pipeline Products by Stage of Development
    • Carotid and Renal Artery Stents – Companies Pipeline Products by Stage of Development
      • Table Carotid and Renal Artery Stents – Companies Pipeline Products by Stage of Development
  • Carotid and Renal Artery Stents Companies and Product Overview
    • Acotec Scientific Holdings Ltd Company Overview
      • Acotec Scientific Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Acotec Scientific Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Carotid Stent - Product Status
        • Table Carotid Stent - Product Description
    • Contego Medical LLC Company Overview
      • Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Neuroguard IEP System - Product Status
        • Table Neuroguard IEP System - Product Description
        • Table Contego Medical LLC - Ongoing Clinical Trials Overview
        • Table Neuroguard IEP System - Protection Against Emboli During Carotid Artery Stenting Using a 3-in-1 Delivery System Comprised of a Post-dilation Balloon, Integrated Embolic Filter and a Novel Carotid Stent II
        • Table Neuroguard IEP System - Protection Against Emboli During caRotid Artery Stenting Using a Neuroguard IEP(R) Direct 3-in-1 Delivery System Comprised oF a pOst-dilation Balloon, integRated eMbolic Filter, and A Novel Carotid stEnt – the PERFORMANCE III Study
    • CR Bard Inc Company Overview
      • CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table VIVEXX Carotid Stent - Product Status
        • Table VIVEXX Carotid Stent - Product Description
    • Evasc Medical Systems Corp Company Overview
      • Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table ROSS - Renal Ostial Stent System - Product Status
        • Table ROSS - Renal Ostial Stent System - Product Description
    • InspireMD Inc Company Overview
      • InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table CGuard Embolic Prevention System - Product Status
        • Table CGuard Embolic Prevention System - Product Description
        • Table Next Gen CGuard - 5F - Product Status
        • Table Next Gen CGuard - 5F - Product Description
        • Table RGuard Renal - Product Status
        • Table RGuard Renal - Product Description
        • Table InspireMD Inc - Ongoing Clinical Trials Overview
        • Table CGuard Embolic Prevention System - A Multicenter, Single-arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting
        • Table CGuard Embolic Prevention System - Acute Stroke of Carotid Artery Bifurcation Origin Treated with Use of the Micronet-covered CGUARD Stent Under Transient Flow Reversal Linked with Thrombus Retrieval: SAFEGUARD-STROKE Study
        • Table CGuard Embolic Prevention System - An Early Feasibility Study (EFS) Assessing the CGuard Embolic Prevention Carotid Stent to Treat Severe Carotid Stenosis or Occlusion
        • Table CGuard Embolic Prevention System - Long-term Outcomes of MicroNet-covered Stent Routine Use for Stroke Prevention in Symptomatic and Increased-risk Asymptomatic Carotid Stenosis Patients Requiring Revascularization by Neurovascular Team Decision: PARADIGM-EXTEND
        • Table CGuard Embolic Prevention System - OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the Cguard Stent in Patients with Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study
        • Table CGuard Embolic Prevention System - Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL)
    • MicroPort Scientific Corp Company Overview
      • MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Taurus Carotid Stent - Product Status
        • Table Taurus Carotid Stent - Product Description
    • Nesstent Ltd. Company Overview
      • Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nesstent Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table NesStent's Stent - Carotid Bifurcation - Product Status
        • Table NesStent's Stent - Carotid Bifurcation - Product Description
    • Palmaz Scientific Inc (Inactive) Company Overview
      • Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Micro-Mesh Covered Carotid Stent - Product Status
        • Table Micro-Mesh Covered Carotid Stent - Product Description
    • SurModics Inc Company Overview
      • SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Renal Stent System - Product Status
        • Table Renal Stent System - Product Description
  • Carotid and Renal Artery Stents- Recent Developments
    • Nov 27, 2023: Inspiremd Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of Cguard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
    • Nov 10, 2023: Microport Appointment of Director
    • Nov 01, 2023: Contego Medical Announces One-Year Outcomes From the Performance II Carotid Stent Trial
    • Nov 01, 2023: Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23
    • Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
    • Oct 16, 2023: Cordis Issues Statement on the CMS Announcement to Expand Coverage of Carotid Stenting
    • Oct 09, 2023: Contego Medical enrols first patient in Neuroguard IEPsystem trial
    • Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business
    • Sep 29, 2023: Barry Slowey Named Vice President and Chief Sustainability Officer
    • Sep 21, 2023: Microport Scientific Corp. Announces 2023 Interim Report
    • Sep 15, 2023: Amber Beauchamp Named Vice President of Global Human Resources
    • Aug 31, 2023: InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
    • Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
    • Aug 24, 2023: Endologix Announces that Lucas Buchanan Joins Board of Directors
    • Aug 11, 2023: W. L. Gore & Associates to Present New Mosa Paper At Gvsets Conference
    • Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024
    • Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
    • Jul 11, 2023: Microport Scientific Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023
    • May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023
    • Apr 26, 2023: MicroPort announces annual results for 2022
    • Apr 12, 2023: Medtronic has a layoff in California
    • Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company
    • Feb 06, 2023: Surmodics Lays off 58 employees
    • Feb 06, 2023: Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
    • Jan 31, 2023: Surmodics to Host Virtual Annual Meeting of Shareholders
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings